This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyl transferase 1 (DGAT -1) , to pharmaceutical compositions containing them , to processes for their preparation, and to their use in therapy, alone or in combination with other triglyceride lowering therapies for the prevention or treatment of diseases related to DGAT- 1 dysfunction or where modulation of DGAT- 1 activity may have therapeutic benefit including but not limited to obesity , obesity related disorders ,genetic (Type 1 , Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia- related disorders , caused by but not limited to lipodystrophy , hypothyroidism ,medications (beta blockers thiazides estrogen , glucocorticoids, transplant) and other factors (pregnancy , alcohol intake) hyperlipoproteinemia chylomicronemia dyslipidemia , non -alcoholic steatohepatitis , diabetes , insulin, resistance , metabolic syndrome cardiovascular outcomes angina excess hair growth (including syndromes associated with hirsutism) , nephrotic syndrome, fibrosis such as mycocardial renal and liver fibrosis hepatitis C virus infection and acne or other skin disorders.
